ATE256662T1 - Amorphe modifikation von torasemid - Google Patents

Amorphe modifikation von torasemid

Info

Publication number: ATE256662T1
Authority: AT; Austria
Prior art keywords: torasemide; amorphous modification; amorphous; modification
Prior art date: 2000-03-20

Application number

AT00920938T

Other languages

English (en)

Inventor

Darko Filic

Miljenko Dumic

Bozena Klepic

Aleksandar Danilovski

Marijan Tudja

Original Assignee

Pliva D D

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-20

Filing date

2000-05-02

Publication date

2004-01-15

2000-05-02 Application filed by Pliva D D filed Critical Pliva D D

2004-01-15 Application granted granted Critical

2004-01-15 Publication of ATE256662T1 publication Critical patent/ATE256662T1/de

Links

NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 title 1
230000004048 modification Effects 0.000 title 1
238000012986 modification Methods 0.000 title 1
229960005461 torasemide Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Oncology (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Communicable Diseases (AREA)
Vascular Medicine (AREA)
Otolaryngology (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyridine Compounds (AREA)
Materials For Medical Uses (AREA)
Enzymes And Modification Thereof (AREA)
Medicinal Preparation (AREA)

AT00920938T 2000-03-20 2000-05-02 Amorphe modifikation von torasemid ATE256662T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HR20000162A HRP20000162B1 (en)	2000-03-20	2000-03-20	Amorphous torasemide modification
PCT/HR2000/000011 WO2001070694A1 (en)	2000-03-20	2000-05-02	Amorphous torasemide modification

Publications (1)

Publication Number	Publication Date
ATE256662T1 true ATE256662T1 (de)	2004-01-15

Family

ID=10947070

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00920938T ATE256662T1 (de)	2000-03-20	2000-05-02	Amorphe modifikation von torasemid

Country Status (29)

Country	Link
US (1)	US6767917B1 (de)
EP (1)	EP1272470B1 (de)
JP (1)	JP2003528083A (de)
KR (1)	KR20020093847A (de)
CN (1)	CN1211368C (de)
AR (1)	AR023788A1 (de)
AT (1)	ATE256662T1 (de)
AU (1)	AU2000241348A1 (de)
BG (1)	BG107208A (de)
BR (1)	BR0017175A (de)
CA (1)	CA2401908A1 (de)
CZ (1)	CZ20023436A3 (de)
DE (1)	DE60007360T2 (de)
EA (1)	EA004950B1 (de)
EE (1)	EE200200534A (de)
ES (1)	ES2213006T3 (de)
GE (1)	GEP20043300B (de)
HR (1)	HRP20000162B1 (de)
HU (1)	HUP0300596A3 (de)
IL (1)	IL151801A0 (de)
IS (1)	IS6551A (de)
MX (1)	MXPA02009210A (de)
NO (1)	NO20024464L (de)
PL (1)	PL357154A1 (de)
PT (1)	PT1272470E (de)
SK (1)	SK15092002A3 (de)
WO (1)	WO2001070694A1 (de)
YU (1)	YU70502A (de)
ZA (1)	ZA200208309B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20020025217A (ko) *	1999-08-11	2002-04-03	추후보정	토르세미드 동질이상
IN192178B (de) *	2001-08-03	2004-03-06	Ranbaxy Lab
AU2004270161A1 (en)	2003-08-28	2005-03-17	Nicox S.A.	Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
EP1855688A4 (de)	2005-02-24	2011-09-14	Nicox Sa	Stickoxidverstärkende diuretische verbindungen, zusammensetzungen und verwendungsverfahren
CN100421662C (zh) *	2005-11-08	2008-10-01	周卓和	托拉塞米分散片及其制备方法和应用
CN104370805B (zh) *	2013-08-13	2016-09-07	天津汉瑞药业有限公司	托拉塞米化合物
CN105949115A (zh) *	2016-05-26	2016-09-21	南京正科医药股份有限公司	一种新晶型托拉塞米
CN115417810B (zh) *	2022-09-22	2023-10-10	南京正科医药股份有限公司	一种托拉塞米晶型ⅰ的精制方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1477664A (en) *	1974-04-17	1977-06-22	Christiaens Sa A	Pyridine derivatives
DE3529529A1 (de) *	1985-08-17	1987-02-19	Boehringer Mannheim Gmbh	Verfahren zur herstellung einer stabilen modifikation von torasemid
GB8816620D0 (en)	1988-07-13	1988-08-17	Lepetit Spa	Rifapentine hydrohalides
CN1072215C (zh) *	1995-02-22	2001-10-03	赫彻斯特药品和化学品公司	无定形吡咯他尼、吡咯他尼多晶型物,其制备方法和用途
IN182496B (de)	1996-02-20	1999-04-17	Reddy Research Foundation
HRP980532B1 (en) *	1998-10-02	2005-06-30	Pliva	Novel crystalline torasemide modification
US5914336A (en) *	1998-06-02	1999-06-22	Boehringer Mannheim Gmbh	Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
KR20020025217A (ko)	1999-08-11	2002-04-03	추후보정	토르세미드 동질이상

2000
- 2000-03-20 HR HR20000162A patent/HRP20000162B1/xx not_active IP Right Cessation
- 2000-04-28 AR ARP000102019A patent/AR023788A1/es unknown
- 2000-05-02 CN CNB008194319A patent/CN1211368C/zh not_active Expired - Fee Related
- 2000-05-02 CZ CZ20023436A patent/CZ20023436A3/cs unknown
- 2000-05-02 DE DE60007360T patent/DE60007360T2/de not_active Expired - Fee Related
- 2000-05-02 PL PL00357154A patent/PL357154A1/xx not_active Application Discontinuation
- 2000-05-02 AU AU2000241348A patent/AU2000241348A1/en not_active Abandoned
- 2000-05-02 IL IL15180100A patent/IL151801A0/xx unknown
- 2000-05-02 US US10/239,024 patent/US6767917B1/en not_active Expired - Fee Related
- 2000-05-02 EA EA200201003A patent/EA004950B1/ru not_active IP Right Cessation
- 2000-05-02 PT PT00920938T patent/PT1272470E/pt unknown
- 2000-05-02 EP EP00920938A patent/EP1272470B1/de not_active Expired - Lifetime
- 2000-05-02 BR BR0017175-1A patent/BR0017175A/pt not_active IP Right Cessation
- 2000-05-02 YU YU70502A patent/YU70502A/sh unknown
- 2000-05-02 AT AT00920938T patent/ATE256662T1/de not_active IP Right Cessation
- 2000-05-02 WO PCT/HR2000/000011 patent/WO2001070694A1/en not_active Ceased
- 2000-05-02 ES ES00920938T patent/ES2213006T3/es not_active Expired - Lifetime
- 2000-05-02 HU HU0300596A patent/HUP0300596A3/hu unknown
- 2000-05-02 KR KR1020027012411A patent/KR20020093847A/ko not_active Withdrawn
- 2000-05-02 EE EEP200200534A patent/EE200200534A/xx unknown
- 2000-05-02 JP JP2001568906A patent/JP2003528083A/ja active Pending
- 2000-05-02 CA CA002401908A patent/CA2401908A1/en not_active Abandoned
- 2000-05-02 GE GE4937A patent/GEP20043300B/en unknown
- 2000-05-02 MX MXPA02009210A patent/MXPA02009210A/es unknown
- 2000-05-02 SK SK1509-2002A patent/SK15092002A3/sk unknown
2002
- 2002-09-17 IS IS6551A patent/IS6551A/is unknown
- 2002-09-18 NO NO20024464A patent/NO20024464L/no not_active Application Discontinuation
- 2002-10-15 ZA ZA200208309A patent/ZA200208309B/en unknown
- 2002-10-21 BG BG107208A patent/BG107208A/xx unknown

Also Published As

Publication number	Publication date
WO2001070694A1 (en)	2001-09-27
KR20020093847A (ko)	2002-12-16
DE60007360T2 (de)	2004-10-07
GEP20043300B (en)	2004-02-10
EA004950B1 (ru)	2004-10-28
EP1272470B1 (de)	2003-12-17
AU2000241348A1 (en)	2001-10-03
US6767917B1 (en)	2004-07-27
DE60007360D1 (de)	2004-01-29
JP2003528083A (ja)	2003-09-24
PT1272470E (pt)	2004-05-31
CZ20023436A3 (cs)	2003-03-12
CA2401908A1 (en)	2001-09-27
IS6551A (is)	2002-09-17
NO20024464L (no)	2002-09-20
MXPA02009210A (es)	2004-09-06
ZA200208309B (en)	2003-10-15
BG107208A (bg)	2003-07-31
YU70502A (sh)	2006-01-16
HUP0300596A2 (hu)	2003-07-28
SK15092002A3 (sk)	2003-05-02
PL357154A1 (en)	2004-07-12
BR0017175A (pt)	2002-12-10
NO20024464D0 (no)	2002-09-18
WO2001070694A8 (en)	2002-03-21
AR023788A1 (es)	2002-09-04
ES2213006T3 (es)	2004-08-16
EP1272470A1 (de)	2003-01-08
CN1211368C (zh)	2005-07-20
HUP0300596A3 (en)	2005-08-29
HRP20000162A2 (en)	2001-12-31
IL151801A0 (en)	2003-04-10
CN1452613A (zh)	2003-10-29
EE200200534A (et)	2004-04-15
EA200201003A1 (ru)	2003-02-27
HRP20000162B1 (en)	2004-06-30

Legal Events

Date

Code

Title

Description

2004-08-15

UEP

Publication of translation of european patent specification

Ref document number: 1272470

Country of ref document: EP

2006-02-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DK1226127T3 (da)	2009-10-19	Substituerede phenylsulfamoylcarboxamider
DE60118908D1 (de)	2006-05-24	Behandlung von mineralischen stoffen
DK1255740T3 (da)	2006-02-06	Substituerede arylpyraziner
ID30187A (id)	2001-11-15	Dongkrak jenis pantagraf
DK1303521T3 (da)	2005-06-13	Tetrahydro-heterocycloazepinyl-pyrimidinderivater
AR028393A1 (es)	2003-05-07	Iminoazidas substituidas
NO20030917L (no)	2003-04-16	Anvendelse
DE60125415D1 (de)	2007-02-01	Formeinsatz
DE50101908D1 (de)	2004-05-13	Zerstäubungsvorrichtung
FI20000510A0 (fi)	2000-03-06	Taajuusmuuttaja
DE60135956D1 (de)	2008-11-13	Zerstäubungsvorrichtung
DE60107074D1 (de)	2004-12-16	Kristallin form ii von cabergolin
DE50112662D1 (de)	2007-08-09	Substituierte benzoylcyclohexenone
AR028302A1 (es)	2003-05-07	Feniluracilos substituidos
ATE342890T1 (de)	2006-11-15	Polymorph v von torasemid
NO20024464L (no)	2002-09-20	Amorf Torasemide-modifikasjon
DE60100632D1 (de)	2003-10-02	Polarisationswandler
NO20032221D0 (no)	2003-05-16	Vibrasjonsseparator
DE50115853D1 (de)	2011-05-26	Übertragung von Datenpaketen
UA4579S (uk)	2001-02-15	Дозиметр-радіометр гамма-бета-випромінювань
FR2810531B1 (fr)	2003-05-23	Trocart de coelio-chirurgie
ITRM20000220A1 (it)	2001-10-22	Cinnamilidenidrazide isonicotinica c15h13n3o
SE0002629D0 (sv)	2000-07-12	Novel compounds and their use
UA4538S (uk)	2001-02-15	Комплект етикеток
UA4058S (uk)	2000-11-15	Комплект етикеток